SCHEMBL4301943

SCHEMBL4301943

Nc1nccc(Oc2ccc3c(C(=O)O)csc3c2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.44
FLT1 P17948 2/20 0.44
FLT4 P35916 2/20 0.44
RET P07949 1/20 0.44
PDGFRB P09619 1/20 0.44
KIT P10721 1/20 0.44
TBXAS1 P24557 1/20 0.40
LOXL2 Q9Y4K0 2/20 0.37
KDM6B O15054 1/20 0.36
KDM4A O75164 1/20 0.36
KDM4B O94953 1/20 0.36
KDM5C P41229 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
KDM2A Q9Y2K7 1/20 0.36
KDM3A Q9Y4C1 1/20 0.36
CDC7 O00311 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
LMNA P02545 1/20 0.34
F10 P00742 1/20 0.34
ROCK1 Q13464 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12124590 0.85 KDR (0.56) KDRFLT1FLT4RETPDGFRB
SCHEMBL1324297 0.85 HSP90AA1 (0.41) KDRFLT1FLT4RETPDGFRB
SCHEMBL4301949 0.84 TBXAS1 (0.41) KDRFLT1RETTBXAS1LOXL2
SCHEMBL1324066 0.81 KDR (0.56) KDRFLT1FLT4RETPDGFRB
SCHEMBL1325271 0.81 KDR (0.51) KDRFLT1FLT4RETPDGFRB
SCHEMBL1325273 0.80 KDR (0.51) KDRFLT1FLT4RETPDGFRB
SCHEMBL1324816 0.80 KDR (0.52) KDRFLT1FLT4RETPDGFRB
SCHEMBL4300918 0.79 KDR (0.44) KDRFLT1FLT4RETPDGFRB
SCHEMBL273582 0.79 KDR (0.63) KDRFLT1FLT4RETPDGFRB
SCHEMBL1324209 0.77 KDR (0.75) KDRFLT1FLT4RETPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030009-A1 Heterobicyclic Carboxamides as Inhibitors for Kinases NOVARTIS AG (CH) 2009-01-29 US claimed
EP-1996578-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES Novartis AG (CH) 2008-12-03 EP claimed
WO-2008009487-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2008-01-24 WO claimed
US-20090030009-A1 Heterobicyclic Carboxamides as Inhibitors for Kinases NOVARTIS AG (CH) 2009-01-29 US disclosed
EP-1996578-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES Novartis AG (CH) 2008-12-03 EP disclosed
WO-2008009487-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030009-A1 Heterobicyclic Carboxamides as Inhibitors for Kinases PHKG1, MAP3K20, CDK2 KDR 1285/4885FLT1 1391/4885FLT4 2012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.